|
Hep C Study Reveals Taribavirin a Good Alternative to Ribavirin
At the end of a 48-week, Phase IIb study, taribavirin shows similar effectiveness as ribavirin in reducing Hepatitis C viral load. However, participants taking taribavirin had a significantly lower rate of anemia....
Schering-Plough Developing Potent Protease Inhibitor for Hepatitis C
An ongoing Phase IIa study on Schering-Plough's next generation Hepatitis C protease inhibitor is encouraging. According to the company, SCH 900518 is 10 times more potent than other medications in this class and is active against highly resistant Hepatitis C...
New Drug Finds Viral Hiding Spots
A new, experimental drug helps the immune system locate a virus by flagging cells that have turned inside out. Hepatitis C is among the viruses that could benefit from Bavituximab's unique strategy of exposing a virus in hiding....
|
|
|
High Incidence of Allograft Cirrhosis in Hepatitis C Virus
Genotype 1b Infection Following Transplantation: Relationship With
Rejection Episodes
|
table 2. Evolution of
Activity and Fibrosis in the First 5 Years After Liver
Transplantation
|
|
| Score |
First Year |
Second Year |
Third Year |
Fourth Year |
Fifth Year |
|
| Grade (activity)* |
n = 78 |
n = 56 |
n = 35 |
n = 19 |
n = 13 |
| No hepatitis, n (%) |
5 (6.4) |
1 (1.8) |
3 (8.6) |
1 (5.3) |
0 (0) |
| Minimal, n (%) |
20 (25.6) |
9 (16.1) |
5 (14.3) |
2 (10.5) |
2 (15.4) |
| Mild, n (%) |
17 (21.8) |
12 (21.4) |
7 (20) |
4 (21.1) |
5 (53.8) |
| Moderate, n (%) |
31 (39.7) |
25 (44.6) |
13 (37.1) |
8 (42.1) |
4 (30.8) |
| Severe, n (%) |
5 (6.4) |
9 (16.1) |
7 (20) |
4 (21.1) |
2 (15.4) |
| Stage (fibrosis) |
n = 78 |
n = 57 |
n = 35 |
n = 18 |
n = 13 |
| None, n (%) |
44 (56.4) |
24 (42.1) |
15 (42.9) |
5 (27.8) |
4 (30.8) |
| Fibrous portal expansion, n (%) |
27 (34.6) |
21 (36.8) |
10 (28.6) |
9 (50) |
6 (46.2) |
| Bridging fibrosis, n (%) |
4 (5.1) |
9 (15.8) |
7 (20) |
1 (5.6) |
3 (23.1) |
| Cirrhosis, n (%) |
3 (3.8) |
3 (5.3) |
3 (8.6) |
3 (16.7) |
0 (0) |
|
| * Activity was
determined by combining the HAI (Knodell) scores for periportal
necrosis (0-6), lobular degeneration and necrosis (0-4), and portal
inflammation (0-4), and defined as follows: 1-2, minimal;
3-6, mild; 7-10, moderate; 11-14, severe. |
|
Return To
Article
table Of Contents
Hepatitis Central
|
|
